The WHO Global Tuberculosis 2021 Report - not so good news and turning the tide back to End TB.

COVID-19 END TB Strategy MDR/XDR-TB New tools Tuberculosis WHO 2021 Global TB Report

Journal

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933

Informations de publication

Date de publication:
Nov 2022
Historique:
received: 10 02 2022
revised: 07 03 2022
accepted: 07 03 2022
pubmed: 25 3 2022
medline: 15 12 2022
entrez: 24 3 2022
Statut: ppublish

Résumé

To review the data presented in the 2021 WHO global TB report and discuss the current constraints in the global response. The WHO global TB reports, consolidate TB data from countries and provide up to date assessment of the global TB epidemic. We reviewed the data presented in the 2021 report. We noted that the 2021 WHO global TB report presents a rather grim picture on the trajectory of the global epidemic of TB including a stagnation in the annual decline in TB incidence, a decline in TB notifications and an increase in estimated TB deaths. All the targets set at the 2018 United Nations High Level Meeting on TB were off track. The sub-optimal global performance on achieving TB control targets in 2020 is attributed to the on-going COVID-19 pandemic, however, TB programs were already off track well before the onset of the pandemic, suggesting that the pandemic amplified an already fragile global TB response. We emphasize that ending the global TB epidemic will require bold leadership, optimization of existing interventions, widespread coverage, addressing social determinants of TB and importantly mobilization of adequate funding required for TB care and prevention.

Identifiants

pubmed: 35321845
pii: S1201-9712(22)00149-7
doi: 10.1016/j.ijid.2022.03.011
pmc: PMC8934249
pii:
doi:

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

S26-S29

Informations de copyright

Copyright © 2022. Published by Elsevier Ltd.

Références

Eur Respir J. 2021 Jun 4;57(6):
pubmed: 33243847
Public Health Rep (1896). 1961 Jan;76:19-24
pubmed: 13694948
J Bras Pneumol. 2018 Apr;44(2):134-144
pubmed: 29791553
N Engl J Med. 2019 Oct 3;381(14):1347-1357
pubmed: 31577876
Eur Respir J. 2022 Mar 24;59(3):
pubmed: 34764184
Pulmonology. 2021 Mar-Apr;27(2):151-165
pubmed: 33547029
Vaccines (Basel). 2021 May 21;9(6):
pubmed: 34063863
Eur Respir J. 2015 Apr;45(4):928-52
pubmed: 25792630
Lancet. 2010 Oct 9;376(9748):1244-53
pubmed: 20923715
Math Biosci. 2012 Apr;236(2):77-96
pubmed: 22387570
Eur Respir J. 2021 Nov 11;58(5):
pubmed: 34446465
Front Immunol. 2020 Oct 08;11:566608
pubmed: 33117351
Afr J Lab Med. 2021 Jun 17;10(1):1413
pubmed: 34230879
Methods Mol Biol. 2022;2410:387-409
pubmed: 34914059
Int Health. 2015 Mar;7(2):114-20
pubmed: 25733561
Int J Infect Dis. 2021 Dec;113 Suppl 1:S100-S103
pubmed: 33716198
Int J Infect Dis. 2021 Dec;113 Suppl 1:S1-S6
pubmed: 33746094
J Prev Med Hyg. 2017 Mar;58(1):E9-E12
pubmed: 28515626

Auteurs

Jeremiah Chakaya (J)

Department of Medicine, Therapeutics, Dermatology and Psychiatry, Kenyatta University, Nairobi, Kenya and Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom. Electronic address: chakaya.jm@gmail.com.

Eskild Petersen (E)

Institute for Clinical Medicine, Aarhus University, Denmark; European Travel Medicine Network, Méditerranée Infection Foundation, Marseille, France. Electronic address: eskild.petersen@gmail.com.

Rebecca Nantanda (R)

Makerere University Lung Institute, College of Health Sciences, Makerere University, Kampala, Uganda. Electronic address: r.nantanda@gmail.com.

Brenda N Mungai (BN)

Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK. Electronic address: brendanyambura2013@gmail.com.

Giovanni Battista Migliori (GB)

Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy. Electronic address: giovannibattista.migliori@icsmaugeri.it.

Farhana Amanullah (F)

Department of Pediatrics, The Indus Hospital and Health Network and the Aga Khan University, Karachi, Pakistan. Electronic address: farhana.amanullah@tih.org.pk.

Patrick Lungu (P)

National TB and Leprosy Programme, Ministry Of Health, Lusaka, Zambia. Electronic address: lungupatrick99@gmail.com.

Francine Ntoumi (F)

Fondation Congolaise pour la Recherche Médicale (FCRM), Brazzaville, Republic of Congo; Faculty of Sciences and Technology, University Marien Ngouabi, Brazzaville, Republic of Congo; University of Tübingen, Tübingen, Germany. Electronic address: fntoumi@fcrm-congo.com.

Nagalingeswaran Kumarasamy (N)

VHS-Infectious Diseases Medical Centre, VHS Hospital, Chennai, India. Electronic address: kumarasamyn@gmail.com.

Markus Maeurer (M)

Champalimaud Centre for the Unknown, Lisbon, Portugal; Medizinische Klinik, Johannes Gutenberg University Mainz, Germany. Electronic address: markus.maeurer@fundacaochampalimaud.pt.

Alimuddin Zumla (A)

Division of Infection and Immunity, Center for Clinical Microbiology, University College London, and NIHR Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, United Kingdom. Electronic address: a.zumla@ucl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH